Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

FDA Panel OKs Newer Antipsychotics for Children

Seroquel, Zyprexa and Geodon have been linked to certain health risks, experts note

By Steven Reinberg
HealthDay Reporter


Related Encyclopedia
 border=
Acidophilus
Acne
Acoustic Neurinoma
Alagille Syndrome
More...

Related Healthscout Videos
 border=
Shutting Down Tremor.
Weighted Belt for Autism?
Teaching Old Docs New Tricks
Lead in Soil.
More...

Related Animations
 border=
Bipolar Disorder Animation
Dental Cavities
Depression
Schizophrenia and the Brain
More...

Related Drug Information
 border=
Adderal XR
Ambien
Avandia
Concerta
More...

Related News Articles
 border=
Childhood Brain Tumors Leave Lasting Mark
Living With Less TV, More Sweat Boosts Weight Loss
Health Tip: Nails Can Reveal Your Health
Folate Levels in Pregnancy Tied to ADHD in Offspring
More...

WEDNESDAY, June 10 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel voted overwhelmingly Wednesday that Seroquel and Zyprexa, two powerful antipsychotic drugs, be approved to treat schizophrenia and bipolar disorder in children aged 13 to 17.

The panel also endorsed Geodon, a third antipsychotic in the same class, as safe and effective for the treatment of bipolar mania in children aged 10 to 17.

Text Continues Below



All three drugs are part of the new-generation "atypical" antipsychotics, currently approved for adult use. The medications have been prescribed "off-label" by many doctors for years to treat schizophrenia and bipolar disorder in children aged 10 to 17, despite possible serious side effects, including diabetes and heart woes.

Seroquel is made by drug maker AstraZeneca. Pharmaceutical giant Lilly makes Zyprexa, and Geodon is made by Pfizer.

There is a pressing need for effective antipsychotics for children, one expert noted.

"Schizophrenia and bipolar disorder are very real illnesses, which collectively affect between 1 percent and 3 percent of all young people," noted Dr. David Fassler, a clinical professor of psychiatry at the University of Vermont College of Medicine, who testified before the panel. "Without treatment, children have problems at school, at home, and with their friends. They're also at increased risk of accidents, hospitalization, and death at an early age from multiple causes, including suicide."

And yet safety concerns plague many of these drugs. In 2004, the FDA ordered AstraZeneca to add a special "black box" warning to Seroquel's packaging, outlining increased risks of hyperglycemia, high blood pressure and diabetes associated with use of the drug. Also, older patients with dementia-related psychosis treated with Seroquel are at an increased risk of death, according to the FDA.

Page:  1 | 2 | 3 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 6/11/2009

Related Links
 border=
From Healthscout's partner site on bipolar, BipolarConnect.com
QUIZ: Test your knowledge of bipolar causes and treatments
DRUGS: Common drugs used to treat bipolar disorder
BASICS: Learn the basics of bipolar disorder





SOURCES: David Fassler, M.D., clinical professor, psychiatry, University of Vermont College of Medicine, Burlington; Diana Zuckerman, Ph.D., president, National Research Center for Women & Families, Washington, D.C.; Ronald T. Brown, Ph.D., dean and professor, public health, Temple University Health Sciences Center, Philadelphia; June 10, 2009, statement, U.S. Food and Drug Administration; June 10, 2009, statement, AstraZeneca, Wilmington, Del.


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy